Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 94.7%

Neg 94.7% Neu 0% Pos 0%

Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.